REG - GSK PLC - Director/PDMR Shareholding
14/02/2023 07:01
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230214:nRSN7905Pa&default-theme=true
RNS Number : 7905P GSK PLC 13 February 2023
GSK plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares
and American Depositary Shares ('ADSs') made to Persons Discharging Managerial
Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in
February 2020 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'),
which were subject to relevant business performance conditions, and the
subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards
were made in 2020 and the three-year performance period commenced on 1 January
2020 and ended on 31 December 2022. The vested shares for the Executive
Directors are now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in
2020 are set out in the following table.
Outcome and Vesting Level
Portion of the Award Measure and Outcome % of maximum % of award
30% Adjusted Free Cash Flow - For the three years ending 31 December 2022, the 100 30.00
Company achieved Adjusted Free Cash Flow calculated in accordance with the
principles for the measure of £13.08bn, which is above the revised target of
£10.47bn required for maximum vesting.
Adjustments to the original target and vesting schedule were set out in detail
in the 2021 Annual Report.
30% Total Shareholder Return - For the three-year period the Company's Total 0 0.00
Shareholder Return ranked 9th, which is below the threshold vesting level
against a comparator group of 10 global pharmaceutical companies including
GSK.
20% Innovation Sales - For the three-year period, the Company achieved revenues 41 8.20
from new products calculated in accordance with the principles for the measure
of £15.368bn, which is slightly below the level of £15.660bn required for
50% vesting. The threshold vesting level was £14.836bn.
20% Pipeline Progress - measure is equally weighted between:
- Pivotal trial starts 88 8.80
- Regulatory approvals 50 5.00
Total vesting for 2020 award 52 52.00
Lapsed 48
The notifications that follow are for awards made to PDMRs and their PCAs and
detail the PSP conditional awards that vested, including dividends accrued, on
10 February 2023. The balance of the award made to each PDMR and PCA has
lapsed.
The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting
date were £14.73 and $35.84.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 237,385
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 125,432
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 48,698
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 26,069
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 78,211
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 36,760
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 29,662
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 13,942
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 3,372
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 1,585
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 110,116
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 4,526
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Technology and Digital Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The number of ADSs vesting on awards granted in 2020 under the Company's 2017
Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 4,065
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Technology and Digital Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$35.7274 2,169
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 90,755
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 42,655
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 57,012
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 26,796
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 41,449
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 19,482
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 48,590
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 22,838
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr T Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 14,038
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr T Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 6,598
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms V Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2020 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 7,141
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms V Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2020 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.7818 3,357
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2023-02-10
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFLESDEDSEIERecent news on GSK
See all newsREG - GSK PLC - Nucala receives positive CHMP opinion for COPD
AnnouncementREG - GSK PLC - Depemokimab receives positive CHMP opinion
AnnouncementREG - Stock Exch Notice - Admission to Trading - 12/12/2025
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Positive CHMP opinion on Arexvy for all adults 18+
Announcement